Genentech Avastin Launch Could Be Slowed By Final Packaging Specifications
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is understood to be in talks with FDA over the optimal dose for Avastin. A delay would allow Bristol's Erbitux to enjoy at least two months on the market before facing a biologic competitor.